Abstract
Background: Thienopyrimidinone is a newly designed, selective fibroblast growth factor receptor 1 (FGFR1) inhibitor with an excellent anticancer effect.
Objective: The goal of the present study was to design and synthesize better FGFR1 inhibitors through modifications of the lead compound thienopyrimidinone.
Methods: In the present study, a series of C-2 substituted derivatives of thienopyrimidinone, namely L1–L16, were synthesized, and their inhibitory effects on FGFR1 were evaluated. The anti-proliferative activities of these compounds were assessed by MTT assay.
Results: Among the novel derivatives, L11 was found to exert remarkable FGFR1 inhibitory activity (79.93% at 10 µM) and anti-proliferative activity, with IC50 values of 2.1, 2.5, and 3.5 M in the FGFR1-overexpressing cell lines, H460, HT-1197, and B16F10, respectively.
Conclusion: Our newly synthesized thienopyrimidinone derivatives may be candidate FGFR1 inhibitors for future development as novel anticancer agents.
Keywords: FGFR1, inhibitor, thienopyrimidinone, design, synthesis, anticancer.
Graphical Abstract
Medicinal Chemistry
Title:Design, Synthesis, and Biological Evaluation of C-2 Substituted 3Hthieno[ 2,3-d]pyrimidin-4-one Derivatives as Novel FGFR1 Inhibitors
Volume: 13 Issue: 8
Author(s): Ping Guo, Zixin Xie, Huan Zhang, Zaikui Zhang , Chao Han , Donghua Cheng, Dan Lin, Yuan Zhang, Xuebao Wang, Xin Guo and Faqing Ye *
Affiliation:
- School of Pharmacy, Wenzhou Medical University, 1210 University Town, Wenzhou, Zhejiang 325035,China
Keywords: FGFR1, inhibitor, thienopyrimidinone, design, synthesis, anticancer.
Abstract: Background: Thienopyrimidinone is a newly designed, selective fibroblast growth factor receptor 1 (FGFR1) inhibitor with an excellent anticancer effect.
Objective: The goal of the present study was to design and synthesize better FGFR1 inhibitors through modifications of the lead compound thienopyrimidinone.
Methods: In the present study, a series of C-2 substituted derivatives of thienopyrimidinone, namely L1–L16, were synthesized, and their inhibitory effects on FGFR1 were evaluated. The anti-proliferative activities of these compounds were assessed by MTT assay.
Results: Among the novel derivatives, L11 was found to exert remarkable FGFR1 inhibitory activity (79.93% at 10 µM) and anti-proliferative activity, with IC50 values of 2.1, 2.5, and 3.5 M in the FGFR1-overexpressing cell lines, H460, HT-1197, and B16F10, respectively.
Conclusion: Our newly synthesized thienopyrimidinone derivatives may be candidate FGFR1 inhibitors for future development as novel anticancer agents.
Export Options
About this article
Cite this article as:
Guo Ping, Xie Zixin, Zhang Huan, Zhang Zaikui , Han Chao , Cheng Donghua, Lin Dan , Zhang Yuan , Wang Xuebao , Guo Xin and Ye Faqing *, Design, Synthesis, and Biological Evaluation of C-2 Substituted 3Hthieno[ 2,3-d]pyrimidin-4-one Derivatives as Novel FGFR1 Inhibitors, Medicinal Chemistry 2017; 13 (8) . https://dx.doi.org/10.2174/1573406413666170623084525
DOI https://dx.doi.org/10.2174/1573406413666170623084525 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Management of Obstetric Fistula: Implication for the Low Resource Areas
Current Women`s Health Reviews Antiangiogenic Therapeutic Approaches in Multiple Myeloma
Current Cancer Drug Targets Regulation of the Activity of the Human Drug Metabolizing Enzyme Arylamine N-Acetyltransferase 1: Role of Genetic and Non Genetic Factors
Current Pharmaceutical Design Designing Novel Therapies Against Sarcomas in the Era of Personalized Medicine and Economic Crisis
Current Pharmaceutical Design Surgical Treatment of Endometriosis
Current Women`s Health Reviews The Emerging Role of TRP Channels in Mechanisms of Temperature and Pain Sensation
Current Neuropharmacology Curcumin and Curcumin-like Molecules: From Spice to Drugs
Current Medicinal Chemistry Signal Transduction Therapy: Challenges to Clinical Trial Design
Current Signal Transduction Therapy Computer-Aided Drug Design for Cancer-Causing H-Ras p21 Mutant Protein
Letters in Drug Design & Discovery Surface Antigens/Receptors for Targeted Cancer Treatment: The GnRH Receptor / Binding Site for Targeted Adenocarcinoma Therapy
Current Cancer Drug Targets Advanced In Silico Approaches for Drug Discovery: Mining Information from Multiple Biological and Chemical Data Through mtk- QSBER and pt-QSPR Strategies
Current Medicinal Chemistry Resveratrol and Clinical Trials: The Crossroad from In Vitro Studies to Human Evidence
Current Pharmaceutical Design Regulation of EMT by Notch Signaling Pathway in Tumor Progression
Current Cancer Drug Targets Telocytes as a Source of Progenitor Cells in Regeneration and Repair Through Granulation Tissue
Current Stem Cell Research & Therapy Involvement of Leukotriene Pathway in the Pathogenesis of Ischemia- Reperfusion Injury and Septic and Non-Septic Shock
Current Vascular Pharmacology Drug-Targeting Strategies for Prostate Cancer
Current Pharmaceutical Design Heat Shock Proteins (HSPs): A Novel Target for Cancer Metastasis Prevention
Current Drug Targets Viral Vectors for Gene-Directed Enzyme Prodrug Therapy
Current Gene Therapy Drug-Metabolizing Enzymes Mechanisms and Functions
Current Drug Metabolism DNA Vaccines for Prostate Cancer
Current Cancer Therapy Reviews